07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Aqua Pharmaceuticals, GlaxoSmithKline sales and marketing update

Aqua acquired U.S. rights to Verdeso 0.05% desonide foam from GlaxoSmithKline's Stiefel Laboratories Inc. subsidiary. The low-potency topical steroid formulated with 0.05% desonide in emollient foam delivery vehicle is approved to treat mild to moderate...
08:00 , Jan 23, 2012 |  BioCentury  |  Emerging Company Profile

Dermira: Success is skin deep

Founded by a management team with a history of growing and selling dermatology assets, Dermira Inc. has set off down a similar path with four molecules that originated at QLT Inc. CEO Thomas Wiggans and...
08:00 , Jan 9, 2012 |  BioCentury  |  Finance

A Remembrance: An authentic giant

A Remembrance: An authentic giant It's been a tough 13 months. Three of the larger-than-life figures in biotech are gone - Frank Baldino of Cephalon Inc. , Jean Deleage of Alta Partners, and now Alex...
01:24 , Nov 23, 2011 |  BC Extra  |  Top Story

Prospect Venture's Barkas passes away

Prospect Venture Partners said Managing Director Alex Barkas died unexpectedly on Monday. Barkas, 64, joined Prospect in 1997 from Kleiner Perkins Caufield & Byers, where he was a partner from 1991-97. He was the founding...
00:14 , Oct 21, 2011 |  BC Extra  |  Financial News

Dermira raises $42M in series A

Dermatology company Dermira Inc. (Redwood City, Calif.) raised $42 million in a series A round from existing investors Bay City Capital and New Enterprise Associates and new investor Canaan Partners. Dermira also acquired fellow dermatology...
07:00 , Apr 11, 2011 |  BioCentury  |  Finance

A Remembrance: The venture capitalist as artist

A Remembrance: The venture capitalist as artist Jean Deleage was one of the privileged few who could count many firsts in his life. But he didn't just help start the biotech industry and then ride...
01:02 , Oct 19, 2010 |  BC Extra  |  Company News

Excaliard names Wiggans chairman

Dermatology company Excaliard Pharmaceuticals Inc. (Carlsbad, Calif.) appointed Thomas Wiggans chairman. Wiggans is the former chairman and CEO of Peplin Inc. , which was acquired in 2009 by Leo Pharma A/S (Ballerup, Denmark), and the...
08:00 , Feb 8, 2010 |  BioCentury  |  Strategy

Out from Down Under

A dearth of funding often forces Australian companies to out-license products too early in development to get any meaningful revenues out of them, because they can't afford to get them to market by themselves. By...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Company News

Corthera, Novartis deal

Novartis will acquire Corthera for $120 million and up to $500 million in development, regulatory and commercial milestones. Novartis will gain Corthera's relaxin , a recombinant human relaxin-H2 in Phase III testing to treat acute...
02:06 , Dec 24, 2009 |  BC Extra  |  Company News

Novartis to acquire Corthera

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire Corthera Inc. (San Mateo, Calif.) for $120 million and up to $500 million in development, regulatory and commercial milestones. Novartis will gain Corthera's relaxin , a recombinant human relaxin-H2...